HC Wainwright restated their buy rating on shares of Aptose Biosciences (NASDAQ:APTO – Free Report) (TSE:APS) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $2.00 price target on the biotechnology company’s stock.
Separately, StockNews.com initiated coverage on Aptose Biosciences in a research note on Saturday, December 7th. They set a “hold” rating for the company.
View Our Latest Stock Report on Aptose Biosciences
Aptose Biosciences Stock Performance
Institutional Trading of Aptose Biosciences
An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 26.62% of the stock is currently owned by hedge funds and other institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading
- Five stocks we like better than Aptose Biosciences
- What is an Earnings Surprise?
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- The Most Important Warren Buffett Stock for Investors: His Own
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.